Chief Scientific Officer @ NewCo (June 2023 - September 2024)
VP, Immunoengineering @ Moderna (November 2022 - May 2023)
VP, Head of Platform Immunology @ Moderna (April 2020 - October 2022)
Head, Immune Cell Engineered Therapeutics (ICE-T), Takeda, Shonan, Japan @ (April 2019 - April 2020)
Senior Medical Director, Immuno-Oncology DDU, Takeda, Cambridge MA, USA @ (April 2019 - April 2020)
Medical Director, Immunology, Gastrointestinal TAU, Takeda, Cambridge MA, USA @ (December 2015 - April 2019)
Associate Scientific Director, Immunology TA, Spring House PA, USA @ (September 2013 - December 2015)
Assistant Professor of Medicine, Immunology, Boston MA, USA @ (May 2007 - September 2013)
Postdoctoral Fellow, Immunology, Boston MA, USA @ (March 2002 - May 2007)
J. Mora Education
Harvard University
Postdoctoral Fellow (Immunology)
Universidad de Chile
Clinical Fellow (Allergy and Immunology Residency Program)
Universidad de Chile
Ph.D. in Biomedical Sciences (Immunology)
Universidad de La Frontera
M.D. (Medicine)
J. Mora Skills
Immunology
Research
Grant Writing
Medicine
Cell Biology
Science
Laboratory
Molecular Biology
Gastroenterology
Drug Discovery
Cell
Cell Culture
Lifesciences
Immunohistochemistry
In Vitro
Biochemistry
Life Sciences
Flow Cytometry
Team Leadership
Cancer Research
Grant Reviewing
Inflammation
Mentoring
Mucosal Immunology
Peer Reviews
Physiology
Principal Investigator
Scientific Papers
Scientist
Target Identification
Team Management
Public Speaking
Biotechnology
Microsoft Excel
Customer Service
Project Management
J. Mora Summary
J. Mora, based in South San Francisco, CA, US, is currently a Chief Scientific Officer at BreezeBio. J. Mora brings experience from previous roles at NewCo, Moderna and Takeda. J. Mora holds a Postdoctoral Fellow in Immunology @ Harvard University. With a robust skill set that includes Immunology, Research, Grant Writing, Medicine, Cell Biology and more. J. Mora has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different J. Mora?
Find contact details for 700 million professionals.